open access
Genotype-phenotype correlations in Polish patients with hypertrophic cardiomyopathy: Preliminary report
Affiliations- Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
- 2nd Department of Cardiology and Angiology, Silesian Center for Heart Diseases, Zabrze, Poland
- 3rd Department of Cardiology, Silesian Center for Heart Diseases, Zabrze, Poland
- Kardio-Med Silesia, Zabrze, Poland
- Department of Cardiac, Vascular and Endovascular Surgery and Transplantology in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, Zabrze, Poland
- 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
open access
Abstract
Abstract
Supp./Additional Files (1)
About this articleTitle
Genotype-phenotype correlations in Polish patients with hypertrophic cardiomyopathy: Preliminary report
Journal
Kardiologia Polska (Polish Heart Journal)
Issue
Article type
Short communication
Pages
482-484
Published online
2022-02-17
Page views
251
Article views/downloads
132
DOI
10.33963/KP.a2022.0052
Pubmed
Bibliographic record
Kardiol Pol 2022;80(4):482-484.
Authors
Tadeusz Osadnik
Anna Frycz-Kurek
Mateusz Lejawa
Martyna Fronczek
Justyna Małyszek-Tumidajewicz
Wioletta Szczurek-Wasilewicz
Karolina Macioł-Skurk
Mariusz Gąsior
Bożena Szyguła-Jurkiewicz
References (11)- Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39): 2733–2779.
- Pysz P, Rajtar-Salwa R, Smolka G, et al. Mavacamten — a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy. Kardiol Pol. 2021; 79(9): 949–954.
- Team RC. R: A Language and Environment for Statistical Computing [Internet]. Vienna: R Foundation for Statistical Computing; 2019. Available online: https: //www.r-project.org/ (Access: January 2022).
- Sabater-Molina M, Pérez-Sánchez I, Hernández Del Rincón JP, et al. Genetics of hypertrophic cardiomyopathy: A review of current state. Clin Genet. 2018; 93(1): 3–14.
- Loar RW, Bos JM, Will ML, et al. Genotype-phenotype correlations of hypertrophic cardiomyopathy when diagnosed in children, adolescents, and young adults. Congenit Heart Dis. 2015; 10(6): 529–536.
- Steriotis AK, Sharma S. Risk stratification in hypertrophic cardiomyopathy. Eur Cardiol. 2015; 10(1): 31–36.
- Kuusisto J. Genetics of hypertrophic cardiomyopathy: what is the next step? Heart. 2020; 106(17): 1291–1292.
- Teekakirikul P, Zhu W, Huang HC, et al. Hypertrophic cardiomyopathy: an overview of genetics and management. Biomolecules. 2019; 9(12).
- Fujino N, Ino H, Hayashi K, et al. et al.. A novel missense mutation in cardiac ryanodine receptor gene as a possible cause of hypertrophic cardiomyopathy: Evidence from familial analysis. Circulation. 2006; 114(18): II-165–915.
- Landstrom AP, Ackerman MJ. Beyond the cardiac myofilament: hypertrophic cardiomyopathy- associated mutations in genes that encode calcium-handling proteins. Curr Mol Med. 2012; 12(5): 507–518.
- Alvarado FJ, Bos JM, Yuchi Z, et al. Cardiac hypertrophy and arrhythmia in mice induced by a mutation in ryanodine receptor 2. JCI Insight. 2019; 5.
